Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Allovir Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALVR
Nasdaq
8731
https://www.allovir.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Allovir Inc
AlloVir, Inc. (ALVR) Upgraded to Buy: Here's What You Should Know
- Jan 25th, 2023 5:00 pm
How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8%
- Jan 25th, 2023 2:55 pm
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
- Jan 25th, 2023 2:40 pm
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
- Jan 9th, 2023 12:00 pm
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2023 12:00 pm
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
- Dec 10th, 2022 10:15 pm
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
- Nov 15th, 2022 12:00 pm
Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting
- Nov 3rd, 2022 1:07 pm
AlloVir Reports Third Quarter 2022 Financial Results
- Nov 3rd, 2022 11:00 am
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully
- Oct 21st, 2022 12:30 pm
Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High?
- Sep 6th, 2022 1:55 pm
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
- Aug 31st, 2022 11:00 am
Does AlloVir, Inc. (ALVR) Have the Potential to Rally 251% as Wall Street Analysts Expect?
- Aug 19th, 2022 1:55 pm
AlloVir Reports Second Quarter 2022 Financial Results
- Aug 4th, 2022 11:00 am
Wall Street Analysts Predict a 447% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know
- Aug 3rd, 2022 1:55 pm
Do Institutions Own AlloVir, Inc. (NASDAQ:ALVR) Shares?
- Aug 1st, 2022 12:09 pm
AlloVir Announces $126.6 Million Registered Direct Offering
- Jul 27th, 2022 11:00 am
AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients
- Jun 7th, 2022 4:07 pm
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
- Jun 7th, 2022 12:30 pm
AlloVir Reports First Quarter 2022 Financial Results
- May 5th, 2022 11:00 am
Scroll